Why Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) has a 57% chance to Drop?

Why Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) has a 57% chance to Drop?

Why Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) has a 57% chance to Drop?

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) is expected to announce second quarter financial results after market close (confirmed) on August 17, 2017. The company added about -14.9% percent in value since last earnings when it was at $12.31. Based on the most relevant historical data, there is a 57 percent probability for share price to go down following the next earnings report. Looking further into earnings reaction history, the stock had moved down 4 times out of last 7 quarters. It has topped earnings-per-share estimates 10% of the time in its last 12 earnings reports. It missed earnings on 9 occasions, and it has met expectations 0 time.

Bellicum Pharmaceuticals, Inc. (BLCM) History

Overall, the average earnings surprise was -7.35 percent over the past four quarters. Back on May 08, 2017, it posted earnings per share at $-0.80 which missed the consensus $-0.70 projection (Negative surprise of -13.67%). Revenue came in at $0.13M versus consensus estimate of $0.07M. The stock dropped -3.33% percent the day following the earnings was released, and on 7th day price change was 5.28% percent.

On March 13, 2017, it posted earnings per share at $-0.74 versus the consensus estimate of $-0.71 (Negative surprise of -4.23%). Revenue of $0.08M was below the $0.09M analysts had expected. The stock dropped -4.83% the day following the earnings was released, and on 7th day price change was 8.37%.

On November 09, 2016, it posted earnings per share at $-0.66, missed the consensus estimate of $-0.63 (Negative surprise of -4.10%). Revenue for the quarter was $0.11M while analysts had expected revenues to come in at $0.07M. The stock gained 6.28% the day following the earnings was released, and on 7th day price change was <spanstyle=’color:red;’>N/A.

On December 31, 1969, it posted earnings per share at $-0.61 compared with the consensus estimate of $-0.57 (Negative surprise of -7.39%). That came on revenues of $0.1M for the quarter. Analysts had expected $0.09M in revenue.</spanstyle=’color:red;’>

Bellicum Pharmaceuticals, Inc. (BLCM) Earnings Expectations

In front of Q3 earnings release, Wall Street is expecting earnings per share of $-0.66. The analysts’ current consensus range is $-0.69-$-0.62 for EPS. The market consensus range for revenue is $ N/A-$130k, with an average of $80k.

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) last closed at $12.90, sending the company’s market cap around $395.00M. The consensus 12-month price target from brokerage firms covering the stock is $28.00. The share price has declined -44.18% from its best level in 52 weeks and advanced -5.29% this year. It recently traded in a range of $-$ at a volume of 2,856,309 shares. The stock ended last trading session with the price nearly 30.17% higher for the last 5 trading days, rebounding 32.85% from its 52-week low.